Article Text

PDF
FRI0201 Immunogenicity of certolizumab pegol without concomitant methotrexate and clinical response in rheumatoid arthritis patients: post-hoc analysis of the hikari study
  1. T. Takeuchi1,
  2. K. Yamamoto2,
  3. H. Yamanaka3,
  4. N. Ishiguro4,
  5. Y. Tanaka5,
  6. K. Eguchi6,
  7. A. Watanabe7,
  8. H. Origasa8,
  9. Y. Wada9,
  10. T. Shoji9,
  11. N. Miyasaka10,
  12. T. Koike11
  1. 1Keio University
  2. 2University of Tokyo
  3. 3Tokyo Women’s Medical University, Tokyo
  4. 4Nagoya University, Nagoya
  5. 5University of Occupational and Environmental Health, Kitakyushu
  6. 6Sasebo City General Hospital, Sasebo
  7. 7Tohoku University, Sendai
  8. 8University of Toyama School of Medicine, Toyama
  9. 9UCB Pharma
  10. 10Tokyo Medical and Dental University, Tokyo
  11. 11NTT Sapporo Medical Center, Sapporo, Japan

Abstract

Background Immunogenicity and subsequent reduction in clinical response is an issue for biological agents in rheumatoid arthritis (RA) treatment.

Objectives To assess immunogenicity and clinical response to certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in RA patients (pts) without concomitant methotrexate (MTX).

Methods Post-hoc analysis of a 24-wk, double-blind (DB) study of CZP 200mg without concomitant MTX (HIKARI study) and subsequent open-label extension (OLE) in Japanese pts with active RA (116 pts).1

Results Anti-CZP antibodies (Abs) were detected in 18 pts (15.5%) at any visit during the first 24 wks. Two anti-CZP profiles were observed: 1) Abs peaked between Wk8–Wk12 (early development, n=7); 2) Abs peaked at/after Wk24 (late development, n=11) (Figure). In 6 pts with early development, anti-CZP Abs decreased to below threshold (≤2.4units/mL) at Wk24, and their plasma CZP level increased at Wk24 (median CZP concentration of 7.7µg/ml), following a drop at Wk8 (35.3 and 2.2µg/ml at Wk6 and Wk8, respectively). In contrast, in pts with late development, Abs appeared mostly at Wk24, and plasma CZP level slowly decreased from Wk8 (median CZP concentrations 27.5 and 2.4µg/ml at Wk8 and Wk24, respectively). ACR20/ACR50/ACR70 responses of early development pts (n=7) were greater than those with late development (n=11) (Table). These results suggest that early, transient development of anti-CZP Abs was not associated with poor long-term clinical response, whereas later development led to loss of response. This observation suggests that when anti-CZP Abs with low affinity to CZP are developed early, they may be adsorbed by the high level of plasma CZP. In contrast, late-developed anti-CZP Abs may reside longer and lead to sustained drug clearance, similar to Abs against other anti-TNF biologics.

Conclusions Anti-CZP Abs were detected in 15.5% of RA pts during 24 wks of treatment without concomitant MTX. Better long-term clinical responses were observed in patients with early vs late anti-CZP Abs development.

References

  1. Yamamoto K. Arthritis Rheum 2011;63(Suppl10);S476

Acknowledgements The authors acknowledge Costello Medical Consulting for writing and editorial assistance which was funded by UCB Pharma.

Disclosure of Interest: T. Takeuchi Grant/research support from: Abbott, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Janssen, Mitsubishi-Tanabe, Nippon Shinyaku, Otsuka, Pfizer, Sanofi-Aventis, Santen, Takeda, Teijin, Consultant for: AstraZeneca, Eli Lilly, Novartis, Mitsubishi-Tanabe, Asahi Kasei, Speakers bureau: Abbott, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer, Takeda, K. Yamamoto Grant/research support from: Pfizer, Abbott, Santen, Mitsubishi-Tanabe, Eisai, UCB Pharma, Consultant for: Pfizer, Abbott, BMS, Roche, Chugai, Mitsubishi-Tanabe, Eisai, H. Yamanaka Grant/research support from: Abbott, Astellas, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer, Takeda, UCB Pharma, Consultant for: Abbott, Astellas, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer, Takeda, UCB Pharma, N. Ishiguro Grant/research support from: Takeda, Mitsubishi-Tanabe, Astellas, Chugai, Abbott, BMS, Eisai, Janssen, Kaken, Pfizer, Speakers bureau: Takeda, Mitsubishi-Tanabe, Astellas, Chugai, Abbott, BMS, Eisai, Janssen, Kaken, Pfizer, Taisho-Toyama, Otsuka, Y. Tanaka Grant/research support from: BMS, MSD, Chugai, Mitsubishi-Tanabe, Astellas, Abbott, Eisai, Janssen, Speakers bureau: Mitsubishi-Tanabe, Abbott, Eisai, Chugai, Janssen, Santen, Pfizer, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Otsuka, Actelion, Eli Lilly, Nippon Kayaku, Quintiles Transnational, Ono, UCB Pharma, K. Eguchi Consultant for: UCB Pharma, A. Watanabe Grant/research support from: Astellas, Daiichi-Sankyo, Kyorin, Shionogi, Taisho, Dainippon-Sumitomo, Taiho, Toyama Chemical, Meiji Seika, Speakers bureau: Abbott, MSD, Otsuka, GSK, Shionogi, Daiichi-Sankyo, Taisho-Toyama, Dainippon-Sumitomo, Mitsubishi-Tanabe, Toyama Chemical, Bayer, Pfizer, H. Origasa Consultant for: Astellas, UCB Pharma, Y. Wada Employee of: UCB Pharma, T. Shoji Employee of: UCB Pharma, N. Miyasaka Grant/research support from: Pfizer, Takeda, Mitsubishi-Tanabe, Chugai, Abbott, Eisai, Astellas, T. Koike Speakers bureau: Pfizer, Chugai, Abbott, Mitsubishi-Tanabe, Takeda, Eisai, Santen, Astellas, Taisho-Toyama, BMS, Teijin, Daiichi-Sankyo, UCB Pharma

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.